Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Inc. presents promising Phase 2a clinical trial data on Lomecel-B™ at the AAIC 2024, showing improvements in cognitive function and brain volume in mild Alzheimer's Disease. The therapy demonstrated safety and efficacy, supporting its potential as a novel treatment.